Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition
Dietrich, P., Kuphal, S., Spruss, T., Hellerbrand, C. and Bosserhoff, A. K.
(2018)
Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
Oncogene 37 (7), pp. 897-911.
Date of publication of this fulltext: 28 Jul 2021 17:23
Article
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | Oncogene | ||||
| Publisher: | Nature | ||||
|---|---|---|---|---|---|
| Place of Publication: | LONDON | ||||
| Volume: | 37 | ||||
| Number of Issue or Book Chapter: | 7 | ||||
| Page Range: | pp. 897-911 | ||||
| Date | 2018 | ||||
| Institutions | Chemistry and Pharmacy > Institute of Pharmacy | ||||
| Identification Number |
| ||||
| Keywords | SMALL-MOLECULE INHIBITION; MEK INHIBITION; METASTATIC MELANOMA; PATHWAY; EXPRESSION; RAF; TUMORIGENESIS; VEMURAFENIB; ACTIVATION; EVOLUTION; | ||||
| Dewey Decimal Classification | 500 Science > 540 Chemistry & allied sciences | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 47461 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric